Revance Therapeutics Inc (RVNC)
5.22
-0.04
(-0.76%)
USD |
NASDAQ |
Oct 04, 16:00
5.22
0.00 (0.00%)
Pre-Market: 20:00
Revance Therapeutics Shareholders Equity (Annual): -151.60M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | -151.60M |
| December 31, 2022 | 12.60M |
| December 31, 2021 | 68.47M |
| December 31, 2020 | 374.29M |
| December 31, 2019 | 225.49M |
| December 31, 2018 | 145.62M |
| December 31, 2017 | 268.84M |
| Date | Value |
|---|---|
| December 31, 2016 | 177.07M |
| December 31, 2015 | 253.25M |
| December 31, 2014 | 176.37M |
| December 31, 2013 | -157.55M |
| December 31, 2012 | -216.73M |
| December 31, 2011 | -155.48M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
-151.60M
Minimum
2023
374.29M
Maximum
2020
105.85M
Average
68.47M
Median
2021
Shareholders Equity (Annual) Benchmarks
| Moderna Inc | 13.85B |
| Pacira BioSciences Inc | 870.13M |
| PetIQ Inc | 221.21M |
| Axonics Inc | 637.56M |
| Anebulo Pharmaceuticals Inc | 3.812M |